Key result
Minimally invasive surgery for clinical T4 colorectal cancer resulted in comparable overall survival to open surgery, while potentially reducing surgical invasiveness.
Why the study?
Indications for minimally invasive surgery in T4 colorectal cancer are controversial because its advantages over open surgery remain unclear.
Does minimally invasive surgery improve overall survival and recurrence-free survival in patients with clinical T4 colorectal cancer compared to open surgery?
Observational (n=75)
No
Does minimally invasive surgery improve overall survival and recurrence-free survival in patients with clinical T4 colorectal cancer compared to open surgery?
Minimally invasive surgery for clinical T4 colorectal cancer is surgically safe and provides similar oncological outcomes to open surgery, with potential benefits of reduced invasiveness and earlier initiation of postoperative chemotherapy.
Answers are grounded in this paper and cite their sources.
MIS associated with comparable survival and less blood loss in T4 colorectal cancer; leaves open need for RCTs before practice change.
The indications of minimally invasive surgery (MIS) for T4 colorectal cancer are controversial because the advantages of MIS are unclear. Therefore, we compared overall survival (OS) and recurrence-free survival (RFS) as the primary endpoint, and short-term outcome, alteration in perioperative laboratory data, and the interval of postoperative chemotherapy from operation as secondary endpoints, between MIS and open surgery (OPEN) using a matched-pair analysis. We explored the advantages of MIS for T4 colorectal cancer. In this retrospective single-institution study, we included 125 patients with clinical T4 colorectal cancer who underwent curative-intent surgery of the primary tumor between October 2010 and September 2019. Conversion cases were excluded. MIS patients were matched to OPEN patients (ratio of 1:2) according to tumor location, clinical T stage, and preoperative treatment. We identified 25 and 50 patients who underwent OPEN and MIS, respectively, including 31 with distant metastasis. Both groups had similar background characteristics. The rate of major morbidities (Clavien-Dindo grade > III) was comparable between the 2 groups (P = .597), and there was no mortality in either group. MIS tended to result in shorter postoperative hospitalization than OPEN (P = .073). Perioperative alterations in laboratory data revealed that MIS suppressed surgical invasiveness better compared to OPEN. Postoperative chemotherapy, especially for patients with distant metastasis who underwent primary tumor resection, tended to be started earlier in the MIS group than in the OPEN group (P = .075). OS and RFS were comparable between the 2 groups (P = .996 and .870, respectively). In the multivariate analyses, MIS was not a significant prognostic factor for poor OS and RFS. MIS was surgically safe and showed similar oncological outcomes to OPEN-with the potential of reduced invasiveness and enhanced recovery from surgery. Therefore, patients undergoing MIS might receive subsequent postoperative treatments earlier.
No takes yet. Share an insight, caveat, or question.
Imaizumi et al. (2022) conducted an observational in Clinical T4 colorectal cancer (n=75). Minimally invasive surgery vs. Open surgery was evaluated on Overall survival (HR 1.036, 95% CI 0.315-3.409, p=0.954). Minimally invasive surgery for clinical T4 colorectal cancer resulted in comparable overall survival to open surgery, while potentially reducing surgical invasiveness.
Synapse has enriched 10 related papers. Consider them for comparative context: